Clinical Trials
40
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (40 trials with phase data)• Click on a phase to view related trials
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Conditions
- Moderate ThrombocytopeniaMyelofibrosis
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 118
- Registration Number
- NCT05980806
- Locations
- 🇧🇬
University Multiprofile Hospital for Active Treatment Sveti George - Base 1, Plovdiv, Bulgaria
🇧🇬University Hospital Sv.Ivan Rilski - Sofia, Sofia, Bulgaria
🇫🇷CHU Tours, Hôpital Bretonneau Service d'Hématologie thérapie cellulaire, Tours Cedex 01, Indre-et-Loire, France
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
- Conditions
- Endometrial Cancer
- Interventions
- Drug: Matching Placebo for selinexor
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 220
- Registration Number
- NCT05611931
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸Jupiter Medical Center, Jupiter, Florida, United States
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 13
- Registration Number
- NCT04854434
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
🇺🇸BRCR Global, Plantation, Florida, United States
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
- Conditions
- Locally Advanced Unresectable or Metastatic Melanoma
- Interventions
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 15
- Registration Number
- NCT04768881
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸TOI Clinical Research, Pasadena, California, United States
🇺🇸BRCR Global, Plantation, Florida, United States
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next